ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets
CompanyDeals

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo announced a strategic partnership with Jiangsu Sinopep‑Allsino Biopharmaceutical Co., Ltd., focused on the global development and commercialization of peptide and oligonucleotide products — uniting Sinopep's scientific, development, and manufacturing…

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Eli Lilly BigHat Biosciences Machine Learning Platform
CompanyDeals

Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies

GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment
CompanyDrug

GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment

Hansoh's HS-20093 ADC Earns BTD for Advanced NSCLC from China's NMPA
CompanyDrug

Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors
CompanyDrug

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors

Sichuan Biokin's BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors
CompanyDrug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors
CompanyDrug

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors

Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
CompanyDrug

Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259

Show More